Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer

Lung cancer is the most common malignant tumor with the highest mortality, and about 84% are non-small cell lung cancer (NSCLC). However, only a small proportion of patients with newly diagnosed lung tumors can receive curative surgery and have a high risk of postoperative recurrence. At present, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Rilan, Li, Lingyu, Chen, Xiao, Chen, Naifei, Song, Wei, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581706/
https://www.ncbi.nlm.nih.gov/pubmed/33163406
http://dx.doi.org/10.3389/fonc.2020.575472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581706/
https://www.ncbi.nlm.nih.gov/pubmed/33163406
http://dx.doi.org/10.3389/fonc.2020.575472

Ejemplares similares